Ardea Biosciences — Corporate Update (November 2011)
49 slides from Ardea Biosciences's corporate update, Nov 7, 2011
Slide 1: Ardea Biosciences Company Update
Ardea Biosciences Company Update November 7, 2011 Exhibit 99.2
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results
Slide 3: Status of Development Programs
MEKI + gemcitabine for advanced pancreatic cancer Gout Gout Status of Development Programs MEKI + sorafenib for primary liver cancer Discovery Preclinical Phase 1 Phase 2 Phase 3 Lesinurad (RDEA594) RDEA3170 Next Generation URAT1 BAY 86-9766 (RDEA119) BAY 86-9766 (RDEA119)
Slide 4: Hyperuricemia/Gout
4 HYPERURICEMIA/GOUT
Slide 5: Gout Unmet Medical Need: Severe Disease Is Not Infrequent
Gout Unmet Medical Need Severe Disease Is Not Infrequent 1. Perez-Ruiz F, Arthritis Rheum 2002;47:356-360 Allopurinol does a very poor job of treating severe disease (Images are courtesy of Nicola Dalbeth) Velocity of Tophi Reduction 0.2 0.4 0.6 0.8 1.2 1.4 1.6 Combination Benzbromarone Allopurinol
Slide 6: Hyperuricemia/Gout
Hyperuricemia/Gout Gout is caused by abnormally elevated levels of serum uric acid (>6.8 mg/dL) Increasing incidence and severity in US: approximately 8 million patients – ~ 90% of patients are “under-excretors” of uric acid • Lesinurad increases urinary excretion of uric acid; returns excretion to
Slide 7: URAT1 Inhibitors Increase the Urinary Excretion of Uric Acid
URAT1 Inhibitors Increase the Urinary Excretion of Uric Acid >99% Reabsorption Excretion ~100% of uric acid is initially filtered through glomerular filtration URAT1 Enomoto; Urat1 identification in Nature May2002 D Levinson & L Sorensen; Renal Handling of Uric Acid Proximal Tubule RDEA594
Slide 8: Why Allopurinol Only Works in 30-40% of Patients and Lesinurad Addition Works
Why Allopurinol Only Works in 30-40% of Patients and the Addition of Lesinurad Works in 80-90% 600-800 mg/day <400 mg/day <400 mg/day 400 mg/day 200 mg/day 600 mg/day <400 mg/day <400 mg/day Lesinurad + XO-Inhibitor Treated Patient XO-Inhibitor Treated Patient Typical Gout Patient Long-term Treated
Slide 9: Competitive Landscape - Allopurinol Results From Large Phase 3 Studies
Allopurinol Results From Uloric® US package Insert* Competitive Landscape - Allopurinol Results From Large Phase 3 Studies APEX 28-week Study FACT 52-week Study CONFIRMS 28-week Study Allopurinol Dose (no. of patients) 300/100mg QD (n=263) 300mg QD (n=242) 300/100mg QD (n=755) % patients with sUA <6
Slide 10: Majority of Patients Do Not Reach sUA Target on Urate Lowering Therapy
Majority of Patients Do Not Reach sUA Target of < 6 mg/dL on Urate Lowering Therapy (ULT) in Clinical Practice 27% 35% 30% 61% 31% 32% 73% 65% 70% 39% 69% 68% 61% 39% Source: BioTrends Chart Review 2010, n=786 (patients on allopurinol and febuxostat) Mild Moderate Severe Mild Moderate Severe Total A
Slide 11: Majority of Patients Are Still Having Flares in Clinical Practice
Majority of Patients (ULT Treated or Not) Are Still Having Flares in Clinical Practice 41% 35% 59% 65% Had Gout Flares Had Gout Flares No Gout Flares No Gout Flares ULT Treated Not Treated Source: BioTrends Chart Review 2010, n=1039 (all patients) Percent of patients that experienced gout flares in
Slide 12: Febuxostat FACT Study
Febuxostat FACT Study Colchicine Prophylaxis • Sharp rise in flares after two months of colchicine was stopped • Improvement in flares with more potent therapy not seen until after week 44 • Same flare rate with allopurinol at 1 month and 1 year
Slide 13: Flare Rate in Month From FACT Trial Shows Clear Relationship to sUA
Flare Rate in Month 12 From FACT Trial Shows Clear Relationship to sUA Abstract 758: MA Becker, et al. ACR Boston November 2007 Serum Urate in the 12 th Month of Treatment by 1 mg/dL 7.0 - <8.0 mg/dl 6.0 - <7.0 mg/dl 5.0 - <6.0 mg/dl 4.0 - <5.0 mg/dl <4.0 mg/dl 8.0 mg/dl
Slide 14: Gout Market Breakdown
Diagnosed Gout 8.3M Allopurinol Responders Gout Pts on ULT 2.6M Allo Inadequate Responders 1.5-1.7M 4 Allopurinol Intolerant 125 - 250K Allopurinol Treated 2.5M Gout Market Breakdown 2 3 Patients Restarting Therapy Trx Refractory Gout ~ 100K 1 (1) BioTrends Chart Review 2010 , for severe gout patien
Slide 15: Study 203: Lesinurad Phase 2b Combination Study with Allopurinol
Allopurinol Treatment (200 mg – 600 mg/day) Study 203: Lesinurad Phase 2b Combination Study with Allopurinol in Allopurinol-Refractory Patients 600 mg Lesinurad Placebo 2-4 weeks 4 weeks 2 weeks Population: – gout patients with serum urate (sUA) mg/dL while receiving a stable dose of allopurinol for
Slide 16: Study 203: Primary Endpoint - Mean Percent Change in Serum Urate at Week 4
Study 203: Primary Endpoint - Mean Percent Change in Serum Urate at Week 4 3 -16 -22 -30 p<0.0001 ITT Population p<0.0001 p<0.0001 Baseline sUA = 6.7 6.4 6.9 7.3 (mg/dL) P-values are for comparison to placebo group using an ANCOVA model -35 -30 -25 -20 -15 -10 -5 Placebo Lesinurad 200mg + Allopurino
Slide 17: Study 203: Percent of Patients with sUA Target at Week 4 - ITT
Study 203: Percent of Patients with sUA < 6 mg/dL at Week 4 – Intent to Treat Analysis* 25% 63% 74% 79% p<0.0001 p<0.0001 p<0.0001 * Patients with missing Week 4 results are analyzed as treatment failures, regardless of the reason for the missing data p-values are for comparison to allopurinol alone
Slide 18: Study 203: Percent of Patients with Serum Urate Target at Last Visit - LOCF
Study 203: Percent of Patients w/ Serum Urate < 6 mg/dL at Last Visit – LOCF Analysis* 28% 71% 76% 87% p<0.0001 p<0.0001 p<0.0001 LOCF analysis used in febuxostat US package insert * Last observation carried forward analysis (LOCF) uses a prior week’s sUA results when Week 4 results are missing p-va
Slide 19: Lesinurad Consistently Lowers sUA Across Renal Function Categories
Lesinurad Consistently Lowers sUA Across Renal Function Categories Study 203 Lesinurad Allopurinol Add-on
Slide 20: Incidence of the Most Frequent Adverse Events
Adverse Events Allopurinol + Lesinurad Dose Group Allopurinol + Incidence of the Most Frequent Adverse Events* 200mg (N=46) n (%) 400mg (N=42) n (%) 600mg (N=48) n (%) Combined Lesinurad (N=136) n (%) Pooled Placebo (N=72) n (%) Any Adverse Event 1 (2.2) 4 (9.5) 5 (10.4) 10 (7.4) 10 (13.9) Diarrhea
Slide 21: Study 203: Safety Continued
Study 203: Safety Continued EULAR 2011 update No Serious Adverse Events (SAEs) in main study 5 discontinuations due to adverse events in main study: 2 combination patients (urticaria, elevated lipase) 1 allopurinol patient (hematuria) and 2 baseline patients on allopurinol + colchicine (QT prolongat
Slide 22: Study 203 - Optional Blinded Extension Period
Lesinurad 200mg / matched placebo + Allopurinol Lesinurad 400mg / matched placebo + Allopurinol Lesinurad 600mg / matched placebo + Allopurinol Optional - Lesinurad 600mg/ matched placebo + increased Allopurinol (in 100 mg increments) Study 203 - Optional Blinded Extension Period After a minimum of
Slide 23: Study 203: Patients Continue to Respond in Long-Term Extension
Study 203: Patients Continue to Respond in Long-Term Extension With 90% Response at 44 Weeks 90% Lesinurad sample sizes before LOCF: 76 71 75 66 31 Data presented with LOCF analysis through Week 28; Week 44 is observed cases Placebo sample sizes before LOCF: 46 47 48 36 11 55%
Slide 24: Study 203: Patients Have >90% Response at 44 Weeks
Study 203: Patients Receiving Lesinurad 200 mg or 400 mg Have >90% Response at 44 Weeks Lesinurad group does not include patients who were escalated to 600 mg at any time. LOCF imputation used through Week 28. Week 44 is observed cases (11 placebo, 21 lesinurad)
Slide 25: Study 203: Patients on Lesinurad 200mg Continue to Decline for 16 Weeks
Study 203: Patients on Lesinurad 200mg Continue to Decline for 16 Weeks n = 22 21 18 19 19 After 4 weeks, non-responding patients can be escalated to 400 mg and then later to 600 mg; patients that moved to higher doses are excluded from this analysis to see the effect of just the mg dose Mean Change
Slide 26: Study Extension: Safety
Study 203 Extension: Safety ~40% higher drop-out rate on placebo than lesinurad, with ~3-times as many patients in the lesinurad arms completing 44 weeks of blinded extension; after 44 weeks most placebo patients are switched to lesinurad Consistently lower flare rates on lesinurad 200 mg than place
Slide 27: Lesinurad Study 111 - Phase 1b Febuxostat and Lesinurad Dose Titration Study
febuxostat 80mg QD febuxostat 80mg QD + 400mg lesinurad febuxostat 80mg QD + 600mg lesinurad febuxostat 40mg QD febuxostat 40mg QD + 400mg lesinurad febuxostat 40mg QD + 600mg lesinurad Lesinurad Study 111 – Phase 1b Febuxostat and Lesinurad Dose Titration Study in Gout Patients Population: – gout p
Slide 28: Study 111: Mean sUA and Percent Change in sUA
RDEA594 Study 111 – Mean sUA and Percent Change in sUA febuxostat Febuxostat+ lesinurad 400 mg Febuxostat+ lesinurad 600 mg febuxostat febuxostat+l lesinurad 400 mg febuxostat+l lesinurad 600 mg febuxostat 40 mg febuxostat 80 mg All 600 mg combination values are at least p<0.05 versus 400 mg combina
Slide 29: Study 111: Combining Lesinurad and Febuxostat Produces Much Greater Responses
Study 111: Combining Lesinurad and Febuxostat Produces Much Greater Responses than Can Be Achieved with Highest Dose of Febuxostat * P<0.05, **P<0.01,***P<0.001 versus FBX 40 mg alone # P<0.05, ## P<0.01,### P<0.001 versus FBX 80 mg alone *** ** ** * * ### ## ## ### 0% 20% 40% 60% 80% 100% 120% FBX
Slide 30: Phase 2b Lesinurad Monotherapy - Design
Study 202 - Phase 2b Lesinurad Monotherapy - Design 600 mg Lesinurad days 2 weeks 4 weeks 2 weeks Labs X X X X X X XX X Screening Period Washout of urate lowering therapy 200 mg Lesinurad Off drug Off drug Off drug 200 mg Placebo 400 mg Lesinurad 200 mg 400 mg Colchicine Treatment Randomize if no go
Slide 31: Phase 2b Monotherapy Study Response Rates for Urate Reduction
Study 202 – Phase 2b Monotherapy Study Response Rates for Urate Reduction ITT population n= P=0.0001 P<0.0001 Plasma urate assay using direct LC-MS method of analysis. 0% 13% 42% 60% 0% 10% 20% 30% 40% 50% 60% 70% Placebo Lesinurad 200 mg Lesinurad 400 mg Lesinurad 600 mg
Slide 32: Response Rates for Plasma Urate Reduction by Baseline Urate Levels
Study 202 – Response Rates for Plasma Urate Reduction by Baseline Urate Levels Baseline sUA ITT population n= Plasma urate assay for response using direct LC-MS method of analysis. 0% 10% 20% 30% 40% 50% 60% 70% 80% Placebo Lesinurad 200 mg Lesinurad 400 mg Lesinurad 600 mg sUA >10 mg/dL sUA < 10 mg
Slide 33: Lesinurad Consistently Lowers sUA Across Renal Function Categories
Lesinurad Consistently Lowers sUA Across Renal Function Categories
Slide 34: Incidence of the Most Frequent Adverse Events
Study 202 - Incidence of the Most Frequent Adverse Events* Adverse Events Lesinurad Dose Group *Adverse events reported by at least 2 subjects that were considered at least possibly related to treatment No Serious Adverse Events Two discontinuations due to adverse events, both on 400 mg dose: one pa
Slide 35: Lesinurad Phase 3 Program
Lesinurad Phase 3 Program Long-term Allopurinol Safety Trial ( LASSO ) – open-label interventional study of allopurinol in gout patients otherwise eligible for our Phase 3 studies Combination Study of Lesinurad in Allopurinol Standard of Care Inadequate Responders ( CLEAR #1 ) – randomized, placebo-
Slide 36: Long-term Allopurinol Safety Study (LASSO)
Long-term Allopurinol Safety Study Evaluating Outcomes in Gout Patients (LASSO - N. America & Global) Population: – Up to 2500 pts with hyperuricemia (sUA 8 mg/dL) at ~300 centers Design: – Provide therapy with allopurinol at the medically appropriate doses; monitor patients for a minimum of 2 month
Slide 37: Combination Study of Lesinurad in Allopurinol Standard of Care Inadequate Responders (CLEAR #1 & #2)
Care Inadequate Population: – Gout patients with sUA > 6.5 mg/dL on stable dose of allopurinol between 300 mg to 800 mg (200 mg acceptable for moderate renal impairment) for 12 weeks – 2 gout flares in preceding 12 months Endpoints: – Primary: proportion of subjects with sUA level < 6.0 mg/dL after
Slide 38: Combination Treatment Study in Subjects with Tophaceous Gout (CRYSTAL)
in S ubjects with T oph A eous Gout Using L esInurad and Febuxostat ( CRYSTAL - Global) wks 1 wk Month 6 primary endpoint (sUA) Month 12 Secondary Endpoints Population: – Gout patients with hyperuricemia (sUA dependent on previous therapy) and 1 measureable tophus – Prospective assessment of patient
Slide 39: Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors (LIGHT)
to Xanthine Oxidase In h ibi t ors ( - Global) Population: – Gout patients with sUA 6.5 mg/dL with medical history in which XO therapy is contraindicated (e.g., hypersensitivity, intolerance, or toxicity) Endpoints: – Primary: Proportion of patients whose sUA levels are < 6.0 mg/dL by 6 months RDEA5
Slide 40: RDEA3170
40 RDEA3170
Slide 41: Comparison Between Uricosuric Agents for Inhibition of Uric Acid Transport by URAT1
Comparison Between Uricosuric Agents for Inhibition of Uric Acid Transport by URAT1
Slide 42: 60% Sustained Reduction in sUA After a Single Dose of RDEA3170 40 mg
60% Sustained Reduction in sUA After a Single Dose of RDEA3170 40 mg N=6, fasted state Time (hr) -80 -70 -60 -50 -40 -30 -20 -10
Slide 43: Cancer
43 CANCER
Slide 44: The Age of Targeted Cancer Treatments
Nexavar Herceptin, Erbitux BAY86-9766 (RDEA119) Bcl-2 Tarceva BAY80-6946 The Age of Targeted Cancer Treatments MEK Ras Raf c-Myc Proliferation Angiogenesis Differentiation Apoptosis cPLA2 PDE4 MNK1/2 Elk-1 MAPKAPK1/3 RTK Mcl-1 c-Jun GF ERK2 ERK2 mTOR AKT PI3K
Slide 45: RDEA119 is Potent, Highly Specific MEK Inhibitor
MEK1/2 Enzyme IC 50 17-50 nM Cellular pERK EC 50 2.5-8.7 nM* RDEA119 is Potent, Highly Specific MEK Inhibitor >100-fold selectivity in kinase panel of 205 enzymes at 10 µM** *Cell lines: Colo205, A375, A431, HT-29 ** In-house data MEK1 & MEK2 MEK1 & MEK2 Ron SRC
Slide 46: Synergy between RDEA119 and Sorafenib in Hepatoma Cancer Lines
Synergy between RDEA119 and Sorafenib in Hepatoma Cancer Lines control Sorafenib- 3.5uM RDEA119- 0.1uM RDEA119 +Sorafenib Huh7, day 6 control Sorafenib-3.5uM RDEA119 - 0.25uM RDEA119 +Sorafenib HepG2, day 6
Slide 47: Current Bayer Clinical Trials with BAY86-9766
Current Bayer Clinical Trials with BAY86-9766* A Phase 2 Trial of BAY86-9766 Plus Sorafenib as First Line Systemic Treatment for Hepatocellular Carcinoma (HCC) A Multi-center, Phase 1/2 Study of BAY86-9766 in Combination With Gemcitabine in Patients With Locally Advanced Inoperable or Metastatic Pan
Slide 48: MEK Inhibitor Program
MEK Inhibitor Program MEK program licensed to Bayer HealthCare on April 27, 2009 – $35 million upfront license fee – $15 million milestone received January 2011 for initiation of Phase 2 study in primary liver cancer by Bayer (NCT01304177) – Bayer has also initiated a Phase 1/2 combination study wit
Slide 49: Financial Position
Financial Position 26.8 million common shares outstanding Summary Statement of Operations (In thousands, except per share data) Nine Months Ended September 30, 2011 Revenue Operating expenses Other income, net $ 5,636 61,460 NET LOSS $(55,807) NET LOSS PER SHARE $(2.11) Condensed Balance Sheet Data